227 related articles for article (PubMed ID: 25892239)
1. Interaction of CDCP1 with HER2 enhances HER2-driven tumorigenesis and promotes trastuzumab resistance in breast cancer.
Alajati A; Guccini I; Pinton S; Garcia-Escudero R; Bernasocchi T; Sarti M; Montani E; Rinaldi A; Montemurro F; Catapano C; Bertoni F; Alimonti A
Cell Rep; 2015 Apr; 11(4):564-76. PubMed ID: 25892239
[TBL] [Abstract][Full Text] [Related]
2. Quantitative proteomics with siRNA screening identifies novel mechanisms of trastuzumab resistance in HER2 amplified breast cancers.
Boyer AP; Collier TS; Vidavsky I; Bose R
Mol Cell Proteomics; 2013 Jan; 12(1):180-93. PubMed ID: 23105007
[TBL] [Abstract][Full Text] [Related]
3. CUB-domain-containing protein 1 overexpression in solid cancers promotes cancer cell growth by activating Src family kinases.
Leroy C; Shen Q; Strande V; Meyer R; McLaughlin ME; Lezan E; Bentires-Alj M; Voshol H; Bonenfant D; Alex Gaither L
Oncogene; 2015 Oct; 34(44):5593-8. PubMed ID: 25728678
[TBL] [Abstract][Full Text] [Related]
4. Effect of the tyrosine kinase inhibitor lapatinib on CUB-domain containing protein (CDCP1)-mediated breast cancer cell survival and migration.
Seidel J; Kunc K; Possinger K; Jehn C; Lüftner D
Biochem Biophys Res Commun; 2011 Oct; 414(1):226-32. PubMed ID: 21945930
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-7 inhibits multiple oncogenic pathways to suppress HER2Δ16 mediated breast tumorigenesis and reverse trastuzumab resistance.
Huynh FC; Jones FE
PLoS One; 2014; 9(12):e114419. PubMed ID: 25532106
[TBL] [Abstract][Full Text] [Related]
6. Transcriptome-wide identification of mRNAs and lincRNAs associated with trastuzumab-resistance in HER2-positive breast cancer.
Merry CR; McMahon S; Forrest ME; Bartels CF; Saiakhova A; Bartel CA; Scacheri PC; Thompson CL; Jackson MW; Harris LN; Khalil AM
Oncotarget; 2016 Aug; 7(33):53230-53244. PubMed ID: 27449296
[TBL] [Abstract][Full Text] [Related]
7. CUB domain-containing protein 1, a prognostic factor for human pancreatic cancers, promotes cell migration and extracellular matrix degradation.
Miyazawa Y; Uekita T; Hiraoka N; Fujii S; Kosuge T; Kanai Y; Nojima Y; Sakai R
Cancer Res; 2010 Jun; 70(12):5136-46. PubMed ID: 20501830
[TBL] [Abstract][Full Text] [Related]
8. The interaction between carcinoembryonic antigen-related cell adhesion molecule 6 and human epidermal growth factor receptor 2 is associated with therapeutic efficacy of trastuzumab in breast cancer.
Iwabuchi E; Miki Y; Kanai A; Miyashita M; Kijima G; Hirakawa H; Suzuki T; Ishida T; Sasano H
J Pathol; 2018 Nov; 246(3):379-389. PubMed ID: 30058236
[TBL] [Abstract][Full Text] [Related]
9. Structural requirements for cub domain containing protein 1 (CDCP1) and Src dependent cell transformation.
Kollmorgen G; Bossenmaier B; Niederfellner G; Häring HU; Lammers R
PLoS One; 2012; 7(12):e53050. PubMed ID: 23300860
[TBL] [Abstract][Full Text] [Related]
10. GDNF induces RET-SRC-HER2-dependent growth in trastuzumab-sensitive but SRC-independent growth in resistant breast tumor cells.
Gardaneh M; Shojaei S; Kaviani A; Behnam B
Breast Cancer Res Treat; 2017 Apr; 162(2):231-241. PubMed ID: 28116540
[TBL] [Abstract][Full Text] [Related]
11. HER2-positive breast cancer cells expressing elevated FAM83A are sensitive to FAM83A loss.
Bartel CA; Jackson MW
PLoS One; 2017; 12(5):e0176778. PubMed ID: 28463969
[TBL] [Abstract][Full Text] [Related]
12. Elevated CDCP1 predicts poor patient outcome and mediates ovarian clear cell carcinoma by promoting tumor spheroid formation, cell migration and chemoresistance.
He Y; Wu AC; Harrington BS; Davies CM; Wallace SJ; Adams MN; Palmer JS; Roche DK; Hollier BG; Westbrook TF; Hamidi H; Konecny GE; Winterhoff B; Chetty NP; Crandon AJ; Oliveira NB; Shannon CM; Tinker AV; Gilks CB; Coward JI; Lumley JW; Perrin LC; Armes JE; Hooper JD
Oncogene; 2016 Jan; 35(4):468-78. PubMed ID: 25893298
[TBL] [Abstract][Full Text] [Related]
13. Tyrosine phosphorylation-mediated YAP1-TFAP2A interactions coordinate transcription and trastuzumab resistance in HER2+ breast cancer.
Zou H; Luo J; Guo Y; Deng L; Zeng L; Pan Y; Li P
Drug Resist Updat; 2024 Mar; 73():101051. PubMed ID: 38219531
[TBL] [Abstract][Full Text] [Related]
14. CUB domain-containing protein 1 is a novel regulator of anoikis resistance in lung adenocarcinoma.
Uekita T; Jia L; Narisawa-Saito M; Yokota J; Kiyono T; Sakai R
Mol Cell Biol; 2007 Nov; 27(21):7649-60. PubMed ID: 17785447
[TBL] [Abstract][Full Text] [Related]
15. FBXL14 abolishes breast cancer progression by targeting CDCP1 for proteasomal degradation.
Cui YH; Kim H; Lee M; Yi JM; Kim RK; Uddin N; Yoo KC; Kang JH; Choi MY; Cha HJ; Kwon OS; Bae IH; Kim MJ; Kaushik N; Lee SJ
Oncogene; 2018 Oct; 37(43):5794-5809. PubMed ID: 29973690
[TBL] [Abstract][Full Text] [Related]
16. Transcriptional repression of HER2 by ANO1 Cl
Fujimoto M; Inoue T; Kito H; Niwa S; Suzuki T; Muraki K; Ohya S
Biochem Biophys Res Commun; 2017 Jan; 482(1):188-194. PubMed ID: 27838298
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer.
Nahta R; Yu D; Hung MC; Hortobagyi GN; Esteva FJ
Nat Clin Pract Oncol; 2006 May; 3(5):269-80. PubMed ID: 16683005
[TBL] [Abstract][Full Text] [Related]
18. CUB-domain-containing protein 1 (CDCP1) activates Src to promote melanoma metastasis.
Liu H; Ong SE; Badu-Nkansah K; Schindler J; White FM; Hynes RO
Proc Natl Acad Sci U S A; 2011 Jan; 108(4):1379-84. PubMed ID: 21220330
[TBL] [Abstract][Full Text] [Related]
19. Identification of CDCP1 as a hypoxia-inducible factor 2α (HIF-2α) target gene that is associated with survival in clear cell renal cell carcinoma patients.
Emerling BM; Benes CH; Poulogiannis G; Bell EL; Courtney K; Liu H; Choo-Wing R; Bellinger G; Tsukazawa KS; Brown V; Signoretti S; Soltoff SP; Cantley LC
Proc Natl Acad Sci U S A; 2013 Feb; 110(9):3483-8. PubMed ID: 23378636
[TBL] [Abstract][Full Text] [Related]
20. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]